Eagle Pharmaceuticals, Inc. (EGRX)
After hours:
| Previous close | 35.91 |
| Open | 35.82 |
| Bid | 25.91 x 1000 |
| Ask | 33.67 x 800 |
| Day's range | 33.48 - 35.75 |
| 52-week range | 24.35 - 56.43 |
| Volume | |
| Avg. volume | 170,406 |
| Market cap | 442.02M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | 20.34 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Eagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace
KOL headshot KOL headshot KOL headshot KOL headshot KOL headshot KOL headshot -- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline programs: Enalare’s ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol -- WOODCLIFF LAKE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Ea
- GlobeNewswire
Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel
-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline programs: Enalare’s ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol -- WOODCLIFF LAKE, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today anno
- GlobeNewswire
Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia
-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as the beginning of 2023 -- -- CAL02 is being developed as an adjunct to the clinically indicated antibiotic treatment -- WOODCLIFF LAKE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administra
